For decades, African nations have relied heavily on imported medications to meet their healthcare needs. Dr. Arnaud Kaboré, a pharmacist and engineer, presents a strategic roadmap for public leaders to achieve pharmaceutical sovereignty by 2045.

Why pharmaceutical independence is no longer optional

Despite progress in some regions, fewer than five African countries operate pharmaceutical manufacturing units capable of exporting beyond their borders. This leaves the continent importing a staggering 94% of its medicines at an annual cost exceeding $18 billion—a figure projected to surpass $30 billion by 2030. The implications go beyond economics.

Over 70% of public health facilities in Africa report critical stockouts at least once per quarter, exposing the continent’s deep structural vulnerabilities. How can the health of 1.4 billion Africans depend on decisions made outside the continent? The Covid-19 pandemic exposed these risks: recurring shortages of essential drugs like amoxicillin, insulin, and anesthetics, alongside chronic inaccessibility to cancer treatments and innovative therapies. The human cost is severe: untreated illnesses, price surges during shortages, and crippled public health programs.

Yet Africa possesses untapped potential:

• A rapidly expanding market: Africa’s pharmaceutical sector could exceed $70 billion by 2030.
• Exceptional biodiversity: over 5,400 documented medicinal plants, some already integrated into approved therapeutic protocols.
• A regulatory momentum: the African Medicines Agency (AMA), ratified by 27 countries, is standardizing regulations across the continent.
• Political determination: nations like Burkina Faso, Rwanda, Egypt, Morocco, Senegal, and South Africa are launching ambitious local production initiatives.

Reimagining Africa’s healthcare future

One critical misstep has been attempting to replicate the models of international pharmaceutical giants without building foundational capabilities or local value chains. Industrialization cannot be achieved through imported equipment alone—it requires developing human expertise, technical know-how, and domestic industrial assets. Otherwise, local production remains costlier than imports, perpetuating dependence on foreign raw materials, technologies, and expertise.

To achieve pharmaceutical sovereignty, African leaders must adopt a methodical, long-term approach grounded in the continent’s unique strengths: a growing market, medicinal biodiversity, regulatory progress, and strong political will. This roadmap must prioritize building local capacity in stages, starting with the most accessible and strategic segments of the pharmaceutical value chain.

Africa must produce medicines where they are needed—starting with essential drugs—and gradually expand to more complex therapies. This vision requires clear strategies, adequate funding, and unwavering political commitment. The goal: heal Africa first, and tomorrow, the world.

Dr. Arnaud Kaboré
Pharmacist and Health Sector Executive Leader

---

Building a sustainable pharmaceutical industry

The path to pharmaceutical sovereignty demands more than rhetoric. It requires:

• Investing in local expertise and technical training programs to develop a skilled workforce.
• Strengthening research and development to harness Africa’s biodiversity for drug discovery.
• Harmonizing regulatory standards through the AMA to facilitate regional trade and production.
• Creating enabling policies that incentivize local manufacturing and reduce reliance on imports.

Success will not come overnight, but with deliberate action, Africa can transform from a consumer of medicines to a global leader in pharmaceutical innovation and production.